Biomerica (BMRA) Competitors $3.15 -0.19 (-5.69%) Closing price 07/11/2025 03:46 PM EasternExtended Trading$2.99 -0.16 (-5.08%) As of 07/11/2025 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BMRA vs. KALA, OKUR, ESLA, BDRX, MAAQ, RANI, MRNS, SNYR, ALLK, and INKTShould you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include KALA BIO (KALA), OnKure Therapeutics (OKUR), Estrella Immunopharma (ESLA), Biodexa Pharmaceuticals (BDRX), Mana Capital Acquisition (MAAQ), Rani Therapeutics (RANI), Marinus Pharmaceuticals (MRNS), Synergy CHC (SNYR), Allakos (ALLK), and MiNK Therapeutics (INKT). These companies are all part of the "pharmaceutical products" industry. Biomerica vs. Its Competitors KALA BIO OnKure Therapeutics Estrella Immunopharma Biodexa Pharmaceuticals Mana Capital Acquisition Rani Therapeutics Marinus Pharmaceuticals Synergy CHC Allakos MiNK Therapeutics KALA BIO (NASDAQ:KALA) and Biomerica (NASDAQ:BMRA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations. Which has higher valuation and earnings, KALA or BMRA? Biomerica has higher revenue and earnings than KALA BIO. Biomerica is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKALA BIO$3.89M9.70-$38.51M-$8.24-0.71Biomerica$5.41M1.48-$5.98M-$2.32-1.36 Do insiders & institutionals hold more shares of KALA or BMRA? 24.6% of KALA BIO shares are held by institutional investors. Comparatively, 22.3% of Biomerica shares are held by institutional investors. 8.3% of KALA BIO shares are held by company insiders. Comparatively, 15.0% of Biomerica shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts recommend KALA or BMRA? KALA BIO currently has a consensus price target of $13.00, suggesting a potential upside of 122.22%. Given KALA BIO's stronger consensus rating and higher possible upside, equities research analysts plainly believe KALA BIO is more favorable than Biomerica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KALA BIO 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Biomerica 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to KALA or BMRA? In the previous week, KALA BIO had 8 more articles in the media than Biomerica. MarketBeat recorded 9 mentions for KALA BIO and 1 mentions for Biomerica. Biomerica's average media sentiment score of 1.87 beat KALA BIO's score of 0.22 indicating that Biomerica is being referred to more favorably in the news media. Company Overall Sentiment KALA BIO Neutral Biomerica Very Positive Is KALA or BMRA more profitable? KALA BIO has a net margin of 0.00% compared to Biomerica's net margin of -85.42%. Biomerica's return on equity of -85.90% beat KALA BIO's return on equity.Company Net Margins Return on Equity Return on Assets KALA BION/A -369.29% -64.99% Biomerica -85.42%-85.90%-61.06% Which has more volatility and risk, KALA or BMRA? KALA BIO has a beta of -1.88, meaning that its share price is 288% less volatile than the S&P 500. Comparatively, Biomerica has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. SummaryKALA BIO and Biomerica tied by winning 8 of the 16 factors compared between the two stocks. Get Biomerica News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMRA vs. The Competition Export to ExcelMetricBiomericaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.02M$2.42B$5.56B$9.11BDividend YieldN/A1.79%5.06%4.01%P/E Ratio-1.369.4228.2620.26Price / Sales1.48732.10435.95101.33Price / CashN/A164.4637.1257.67Price / Book1.014.608.045.49Net Income-$5.98M$31.26M$3.19B$250.45M7 Day Performance-4.69%4.80%3.62%4.78%1 Month Performance-1.56%8.17%5.98%9.58%1 Year Performance10.33%-3.88%29.39%16.41% Biomerica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMRABiomerica1.1328 of 5 stars$3.15-5.7%N/A+10.3%$8.02M$5.41M-1.3660KALAKALA BIO3.9652 of 5 stars$5.28+3.5%$13.50+155.7%-21.8%$32.91M$3.89M-0.6430News CoverageAnalyst ForecastOKUROnKure Therapeutics3.5603 of 5 stars$2.39+0.4%$32.33+1,252.9%N/A$32.15MN/A-0.45N/APositive NewsESLAEstrella Immunopharma3.1847 of 5 stars$0.88+0.2%$16.00+1,714.7%-38.0%$31.83MN/A-3.39N/APositive NewsGap DownBDRXBiodexa Pharmaceuticals0.308 of 5 stars$0.87+0.8%N/AN/A$31.38M$470K0.0020Positive NewsMAAQMana Capital AcquisitionN/A$3.80+3.3%N/A+654.5%$30.88MN/A0.001RANIRani Therapeutics1.8613 of 5 stars$0.54+0.2%$7.33+1,267.4%-82.6%$30.78M$1.20M-0.54110MRNSMarinus Pharmaceuticals2.2251 of 5 stars$0.55-0.2%$3.92+613.3%-59.9%$30.32M$30.99M-0.22110SNYRSynergy CHC3.9718 of 5 stars$3.37+4.0%$10.00+196.7%N/A$29.79M$34.83M0.0040ALLKAllakos2.9411 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190INKTMiNK Therapeutics1.2028 of 5 stars$7.28+0.6%$37.50+415.5%+472.9%$28.82MN/A-2.8930Trending NewsGap Up Related Companies and Tools Related Companies KALA BIO Alternatives OnKure Therapeutics Alternatives Estrella Immunopharma Alternatives Biodexa Pharmaceuticals Alternatives Mana Capital Acquisition Alternatives Rani Therapeutics Alternatives Marinus Pharmaceuticals Alternatives Synergy CHC Alternatives Allakos Alternatives MiNK Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMRA) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomerica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomerica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
